NCT07920679 Efficacy and Safety of K-CAB(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERD
| NCT ID | NCT07920679 |
| Status | Recruiting |
| Phase | — |
| Sponsor | HK inno.N Corporation |
| Condition | Maintenance Therapy Following Treatment for Gastroesophageal Reflux Disease(GERD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 12,868 participants |
| Start Date | 2025-08-14 |
| Primary Completion | 2030-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 12,868 participants in total. It began in 2025-08-14 with a primary completion date of 2030-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess heartburn and acid regurgitation symptoms during long-term administration of K-CAB Tab/K-CAB ODT(Tegoprazan) 25 mg in patients with GERD in routine clinical practice. The study will also evaluate safety information, including important potential risks.
Eligibility Criteria
Inclusion Criteria: 1. Aged 19 years or older on the date written informed consent is obtained 2. Determined by the investigator, based on medical judgment, to receive K-CAB Tab/K-CAB ODT 25 mg 3. Scheduled to receive K-CAB Tab/K-CAB ODT 25 mg, as maintenance therapy following treatment for gastroesophageal reflux disease (GERD) 4. Voluntarily agrees to participate in the study and provides written informed consent Exclusion Criteria: 1. Individuals who meet any of the contraindications listed under "Contraindications" in the "Precautions for Use" section of the approved prescribing information for K-CAB Tab/K-CAB ODT 25 mg 2. Individuals whom the investigator considers unsuitable for participation in this study for any other reason
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07920679 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Maintenance Therapy Following Treatment for Gastroesophageal Reflux Disease(GERD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07920679 currently recruiting?
Yes, NCT07920679 is actively recruiting participants. Contact the research team at yongan.jeong@inno-n.com for enrollment information.
Where is the NCT07920679 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07920679 clinical trial?
NCT07920679 is sponsored by HK inno.N Corporation. The trial plans to enroll 12,868 participants.